In a new study published in JAMA Network Open, researchers at Thomas Jefferson University have developed a novel screening tool to measure digital health readiness, which will be critical in addressing barriers to telehealth adoption among diverse patient populations.
IDRx raises $120m to fund gastric tumour trials for lead TKI therapy
In 2022, IDRx raised $122m in Series A financing and licensed two TKI inhibitors – IDRX-42 from Merck KGaA, and IDRX-73 from Blueprint Medicines. Image
August 7, 2024